NCT01340040 - Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

May 31, 2012

Conditions

CancerAdvanced Solid Malignancies

Interventions

DRUG

MEDI-573

MEDI-573 will be administrated once 7 days in Cohort 1 and 2, and once every 21 days in Cohort 3 as a IV infusion as part of a 21-day treatment cycle.

Trial Locations (1)

Unknown

Research Site, Matsuyama